Charles River Laboratories International, Inc. logo
Charles River Laboratories International, Inc. (CRL)
Compare

Charles River Laboratories International, Inc. (CRL) PE Ratio: N/A

The P/E ratio for Charles River Laboratories International, Inc. (CRL) is N/A as of Friday, June 12, 2026.

CRL PE Ratio Chart

CRL PE Ratio
769.40+2911.35% 1Y
Zoom

CRL Average PE Ratio Chart

CRL PE Ratio Metrics

PE RATIO

N/A

PE RATIO AVG TTM

225.66

PE RATIO AVG 3Y

91.39

PE RATIO AVG 5Y

72.20

PE RATIO AVG 10Y

51.48

PE RATIO AVG 15Y

44.78

PE RATIO AVG 20Y

48.33

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

CRL Competitors' PE Ratio

NAMEMARKET CAPPE RATIOTTM3Y5Y
Charles River Laboratories International, Inc. (CRL)$9.06BN/A225.6691.3972.20
Tempus AI, Inc. (TEM)$8.65BN/AN/AN/AN/A
Bio-Rad Laboratories, Inc. (BIO)$7.91B48.1823.8223.8212.07
Baxter International Inc. (BAX)$10.58BN/A44.5334.4137.43
Hims & Hers Health, Inc. (HIMS)$6.44BN/A61.9688.4888.48
Align Technology, Inc. (ALGN)$12.64B29.6229.2742.8547.76
Solventum Corporation (SOLV)$13.72B9.7018.8717.0717.07
Hologic, Inc. (HOLX)$16.97B31.6728.1230.0822.83
23andMe Holding Co. (ME)$15.31MN/AN/AN/AN/A
Moderna, Inc. (MRNA)$19.70BN/A15.4632.5132.51

P/E Comparison

Trailing P/E

N/A

Forward P/E

15.3

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$188.06

÷

Forward EPS (Est.)

$12.33

=

Forward P/E

15.25

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

Charles River Laboratories International, Inc. PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Charles River Laboratories International, Inc. PE Ratio FAQ

What is the P/E ratio for Charles River Laboratories International, Inc. (CRL)?
The P/E ratio for CRL stock is N/A.
What is the TTM average P/E ratio for Charles River Laboratories International, Inc. (CRL)?
The TTM average P/E ratio for CRL stock is 225.66.
What is the 3Y average P/E ratio for Charles River Laboratories International, Inc. (CRL)?
The 3Y average P/E ratio for CRL stock is 91.39.
What is the 5Y average P/E ratio for Charles River Laboratories International, Inc. (CRL)?
The 5Y average P/E ratio for CRL stock is 72.20.
What is the 10Y average P/E ratio for Charles River Laboratories International, Inc. (CRL)?
The 10Y average P/E ratio for CRL stock is 51.48.
What is the 15Y average P/E ratio for Charles River Laboratories International, Inc. (CRL)?
The 15Y average P/E ratio for CRL stock is 44.78.
What is the 20Y average P/E ratio for Charles River Laboratories International, Inc. (CRL)?
The 20Y average P/E ratio for CRL stock is 48.33.

Charles River Laboratories International, Inc. PE Ratio History

DATEPE RATIO
2025-05-06769.40
2025-05-05796.27
2025-05-02789.73
2025-05-01779.27
2025-04-30790.80
2025-04-29781.93
2025-04-28767.20
2025-04-25764.40
2025-04-24771.73
2025-04-23726.67
2025-04-22712.60
2025-04-21684.47
2025-04-17707.00
2025-04-16695.00
2025-04-15706.13
2025-04-14710.67
2025-04-11665.00
2025-04-10666.33
2025-04-09927.13
2025-04-08824.07
2025-04-07893.80
2025-04-04912.67
2025-04-03939.87
2025-04-02995.20
2025-04-01973.27
2025-03-311003.47
2025-03-281037.00
2025-03-271053.73
2025-03-261055.00
2025-03-251075.67
2025-03-241113.20
2025-03-211115.20
2025-03-201102.33
2025-03-191159.20
2025-03-181179.60
2025-03-171166.73
2025-03-141140.27
2025-03-131112.87
2025-03-121137.27
2025-03-111110.87
2025-03-101167.47
2025-03-071172.80
2025-03-061128.47
2025-03-051117.00
2025-03-041095.40
2025-03-031090.00
2025-02-281102.07
2025-02-271099.20
2025-02-261119.73
2025-02-251114.00
2025-02-241136.73
2025-02-211086.80
2025-02-201081.67
2025-02-191100.00
2025-02-1819.32
2025-02-1419.02
2025-02-1319.17
2025-02-1219.27
2025-02-1119.39
2025-02-1020.01
2025-02-0720.50
2025-02-0620.81
2025-02-0520.76
2025-02-0420.42
2025-02-0320.23
2025-01-3120.62
2025-01-3020.72
2025-01-2920.23
2025-01-2820.48
2025-01-2720.76
2025-01-2420.65
2025-01-2320.88
2025-01-2221.05
2025-01-2121.25
2025-01-1720.46
2025-01-1620.75
2025-01-1521.77
2025-01-1422.29
2025-01-1323.80
2025-01-1023.29
2025-01-0823.52
2025-01-0723.75
2025-01-0623.72
2025-01-0323.25
2025-01-0222.86
2024-12-3123.10
2024-12-3022.96
2024-12-2723.30
2024-12-2623.36
2024-12-2423.32
2024-12-2323.20
2024-12-2023.25
2024-12-1922.80
2024-12-1822.92
2024-12-1723.70
2024-12-1623.79
2024-12-1323.84
2024-12-1224.31
2024-12-1124.22
2024-12-1024.66
2024-12-0925.25
2024-12-0624.01
2024-12-0523.97
2024-12-0424.95
2024-12-0324.94
2024-12-0225.19
2024-11-2924.91
2024-11-2724.98
2024-11-2624.75
2024-11-2525.19
2024-11-2224.50
2024-11-2124.30
2024-11-2023.52
2024-11-1923.29
2024-11-1823.47
2024-11-1523.50
2024-11-1424.64
2024-11-1325.85
2024-11-1227.03
2024-11-1127.62
2024-11-0826.96
2024-11-0726.32
2024-11-0626.81
2024-11-0522.60
2024-11-0421.85
2024-11-0121.67
2024-10-3121.39
2024-10-3021.72
2024-10-2922.04
2024-10-2822.34
2024-10-2521.81
2024-10-2421.88
2024-10-2322.35
2024-10-2222.27
2024-10-2123.36
2024-10-1823.69
2024-10-1723.69
2024-10-1623.37
2024-10-1523.22
2024-10-1423.13
2024-10-1123.11
2024-10-1022.93
2024-10-0922.48
2024-10-0822.37
2024-10-0722.66
2024-10-0422.84
2024-10-0322.71
2024-10-0223.10
2024-10-0123.24
2024-09-3023.59
2024-09-2723.75
2024-09-2623.74
2024-09-2523.10
2024-09-2424.03
2024-09-2324.40
2024-09-2024.65
2024-09-1925.10
2024-09-1824.68
2024-09-1724.70
2024-09-1624.40
2024-09-1323.79
2024-09-1223.27
2024-09-1123.18
2024-09-1022.76
2024-09-0922.53
2024-09-0622.51
2024-09-0522.90
2024-09-0422.97
2024-09-0323.00
2024-08-3023.68
2024-08-2923.87
2024-08-2823.59
2024-08-2724.35
2024-08-2624.50
2024-08-2324.58
2024-08-2224.11
2024-08-2124.48
2024-08-2024.25
2024-08-1924.43
2024-08-1624.18
2024-08-1524.20
2024-08-1423.78
2024-08-1324.37
2024-08-1223.27
2024-08-0924.07
2024-08-0824.18
2024-08-0723.95
2024-08-0626.92
2024-08-0526.64
2024-08-0227.48
2024-08-0128.57
2024-07-3128.72
2024-07-3028.86
2024-07-2927.99
2024-07-2627.47
2024-07-2526.10
2024-07-2426.17
2024-07-2325.92
2024-07-2226.78
2024-07-1925.68
2024-07-1825.72
2024-07-1726.25
2024-07-1626.74
2024-07-1525.44
2024-07-1225.43
2024-07-1124.81
2024-07-1023.85
2024-07-0923.75
2024-07-0823.82
2024-07-0523.49
2024-07-0323.70
2024-07-0223.70
2024-07-0123.91
2024-06-2824.30
2024-06-2724.39
2024-06-2624.32
2024-06-2524.28
2024-06-2424.69
2024-06-2124.89
2024-06-2024.66
2024-06-1824.68
2024-06-1724.52
2024-06-1424.64
2024-06-1324.99
2024-06-1225.16
2024-06-1124.76
2024-06-1025.24
2024-06-0725.27
2024-06-0626.07
2024-06-0525.43
2024-06-0424.73
2024-06-0324.46
2024-05-3124.52
2024-05-3024.67
2024-05-2924.88
2024-05-2825.24
2024-05-2425.55
2024-05-2325.59
2024-05-2225.76
2024-05-2126.06
2024-05-2026.24
2024-05-1726.07
2024-05-1626.44
2024-05-1527.36
2024-05-1427.39
2024-05-1326.87
2024-05-1026.84
2024-05-0927.07
2024-05-0825.55
2024-05-0725.66
2024-05-0625.55
2024-05-0325.35
2024-05-0224.96
2024-05-0125.26
2024-04-3024.86
2024-04-2925.20
2024-04-2624.87
2024-04-2524.74
2024-04-2426.00
2024-04-2326.07

Showing the most recent 260 of 4,406 data points. The chart above shows the full history.

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA
18,700 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
James C. Foster